Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 1:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 262 matching trials from the live ClinicalTrials.gov search.
Conditions
IPF
Interventions
Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
Drug
Lead sponsor
Michael Donahoe
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Simtuzumab, Simtuzumab placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
45 Years to 85 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
Conditions
Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease
Interventions
Lung Spheroid Stem Cells 100 million, Lung Spheroid Stem Cells 200 million
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
35 Years to 80 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more
Conditions
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Stanford, California
Conditions
Idiopathic Pulmonary Fibrosis, IPF
Interventions
Tazarotene (GRI-0621), Placebo
Drug
Lead sponsor
GRI Bio Operations, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Newport Beach, California • Jacksonville, Florida • The Bronx, New York + 2 more
Conditions
Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
Pulmonary Care and Research Collaborative Limited
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pulmonary Fibrosis, Lung Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Idiopathic Pulmonary Fibrosis, IPF
Interventions
MN-001, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Hershey, Pennsylvania
Completed Not applicable Interventional

Palliative Care Planner (PCplanner)

NCT05095363
Conditions
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Interventions
PCplanner
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Idiopathic Pulmonary Fibrosis, Depression, Anxiety, Depressive Disorder, Anxiety Disorders, Anxiety Depression
Interventions
Palliative Care, Standard of Care
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Saracatinab, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Denver, Colorado • New Haven, Connecticut • New York, New York + 1 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
SUPPORT, Currently Available Printed Material
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
45 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
IW001
Drug
Lead sponsor
ImmuneWorks
Industry
Eligibility
35 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 8 more
Conditions
Constipation Chronic Idiopathic, Cystic Fibrosis
Interventions
Maralixibat 9.5 MG/ML [Livmarli]
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
1 Year to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Metformin, Matching Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
TRK-250, Placebo
Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
40 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 8 more
Completed No phase listed Observational Accepts healthy volunteers Results available

Families-At-risk for Interstitial Lung Disease Study

NCT03641742
Conditions
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 100 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis, Cough
Interventions
interferon-alpha lozenges, placebo lozenges
Drug
Lead sponsor
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Industry
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Lubbock, Texas
Conditions
Persistent Cough in IPF, Chronic Cough, IPF
Interventions
RVT-1601, Placebo
Drug
Lead sponsor
Respivant Sciences GmbH
Industry
Eligibility
40 Years to 89 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
28
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 25 more
Conditions
Pulmonary Fibrosis
Interventions
placebo, BIBF 1120
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Scottsdale, Arizona • San Francisco, California • Santa Barbara, California + 23 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
SAR156597, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
18
States / cities
Phoenix, Arizona • Jacksonville, Florida • Loxahatchee Groves, Florida + 15 more
Conditions
Ambulatory IPF
Interventions
Rituximab, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib, Placebo, Sildenafil
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Stamford, Connecticut • Jacksonville, Florida + 13 more